BofA Securities analyst Travis Steed maintains $Boston Scientific (BSX.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 64.1% and a total average return of 8.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Boston Scientific (BSX.US)$'s main analysts recently are as follows:
Boston Scientific has delivered a quarter that exceeded expectations from all angles, despite the high anticipations. Nonetheless, the shares are currently under pressure due to the announced suspension of the AVANT GUARD clinical trial, which is investigating Farapulse in a new patient segment. It's essential to note that this patient segment is not currently being treated, there are certain observations under assessment, and the expectation is for enrollment to continue shortly.
Boston Scientific's Q3 outcomes were described as 'impressive', and the company's management has elevated its 2024 guidance, with expectations to conclude the year with +15% organic sales growth. Despite a temporary halt in the EP trial AVANTGUARD, which influenced the stock negatively, the reaction is perceived to be exaggerated according to key opinion leader assessments.
The AVANT Guard trial setback is not associated with a mortality event or initiated by the FDA, and the momentum of global Farapulse is viewed as sustainable over the medium term. It is believed that the current pullback in Boston Scientific shares offers a compelling entry point.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美銀證券分析師Travis Steed維持$波士頓科學 (BSX.US)$買入評級。
根據TipRanks數據顯示，該分析師近一年總勝率為64.1%，總平均回報率為8.2%。
此外，綜合報道，$波士頓科學 (BSX.US)$近期主要分析師觀點如下：
儘管期望很高，但從各個角度來看，波士頓科學的季度業績都超出了預期。儘管如此，由於宣佈暫停Avant GUARD臨床試驗，該股目前仍處於壓力之下，該股正在調查新患者領域的Farapulse。值得注意的是，該患者群目前尚未接受治療，有某些觀察結果正在評估中，預計很快就會繼續入組。
波士頓科學第三季度的業績被描述爲 「令人印象深刻」，該公司的管理層提高了2024年的預期，預計今年年底有機銷售增長將達到+15％。儘管EP試驗AVANTGUARD暫時停止，對該股產生了負面影響，但根據主要意見領袖的評估，這種反應被認爲被誇大了。
Avant Guard試驗的挫折與死亡事件無關，也與美國食品藥品管理局發起的死亡事件無關，全球Farapulse的勢頭被認爲在中期內是可持續的。據信，波士頓科學公司股票當前的回調提供了一個引人注目的切入點。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
